| Combination of aptamer with gold nanoparticles for electrochemical signal amplification: application to sensitive detection of platelet-derived growth factor J Wang, W Meng, X Zheng, S Liu, G Li Biosensors and Bioelectronics 24 (6), 1598-1602, 2009 | 156 | 2009 |
| Concordance of genomic alterations between primary and recurrent breast cancer F Meric-Bernstam, GM Frampton, J Ferrer-Lozano, R Yelensky, ... Molecular cancer therapeutics 13 (5), 1382-1389, 2014 | 123 | 2014 |
| Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer KM McAndrews, Y Chen, JK Darpolor, X Zheng, S Yang, JL Carstens, B Li, ... Cancer discovery 12 (6), 1580-1597, 2022 | 113 | 2022 |
| Clinical actionability enhanced through deep targeted sequencing of solid tumors K Chen, F Meric-Bernstam, H Zhao, Q Zhang, N Ezzeddine, L Tang, Y Qi, ... Clinical chemistry 61 (3), 544-553, 2015 | 106 | 2015 |
| Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype GL Johanning, GG Malouf, X Zheng, FJ Esteva, JN Weinstein, ... Scientific reports 7 (1), 41960, 2017 | 88 | 2017 |
| Induction of OTUD1 by RNA viruses potently inhibits innate immune responses by promoting degradation of the MAVS/TRAF3/TRAF6 signalosome L Zhang, J Liu, L Qian, Q Feng, X Wang, Y Yuan, Y Zuo, Q Cheng, Y Miao, ... PLoS pathogens 14 (5), e1007067, 2018 | 84 | 2018 |
| Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple-negative breast cancer KW Evans, E Yuca, SS Scott, M Zhao, N Paez Arango, CX Cruz Pico, ... Cancer research 81 (21), 5572-5581, 2021 | 82 | 2021 |
| NF-κB-inducing kinase maintains T cell metabolic fitness in antitumor immunity M Gu, X Zhou, JH Sohn, L Zhu, Z Jie, JY Yang, X Zheng, X Xie, J Yang, ... Nature immunology 22 (2), 193-204, 2021 | 68 | 2021 |
| Metastasis regulation by PPARD expression in cancer cells X Zuo, W Xu, M Xu, R Tian, MJ Moussalli, F Mao, X Zheng, J Wang, ... JCI insight 2 (1), 2017 | 67 | 2017 |
| The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network X Tan, P Banerjee, X Liu, J Yu, DL Gibbons, P Wu, KL Scott, L Diao, ... The Journal of clinical investigation 128 (4), 1267-1282, 2018 | 65 | 2018 |
| Quaternary organization of GPIb-IX complex and insights into Bernard-Soulier syndrome revealed by the structures of GPIbβ and a GPIbβ/GPIX chimera PA McEwan, W Yang, KH Carr, X Mo, X Zheng, R Li, J Emsley Blood, The Journal of the American Society of Hematology 118 (19), 5292-5301, 2011 | 64 | 2011 |
| Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer F Meric-Bernstam, X Zheng, M Shariati, S Damodaran, C Wathoo, ... JCO precision oncology 2, 1-15, 2018 | 63 | 2018 |
| Ability to generate patient-derived breast cancer xenografts is enhanced in chemoresistant disease and predicts poor patient outcomes PF McAuliffe, KW Evans, A Akcakanat, K Chen, X Zheng, H Zhao, ... PloS one 10 (9), e0136851, 2015 | 61 | 2015 |
| Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis in pancreatic cancer JL Carstens, S Yang, PC De Sampaio, X Zheng, S Barua, KM McAndrews, ... Cell reports 35 (2), 2021 | 55 | 2021 |
| A population of heterogeneous breast cancer patient-derived xenografts demonstrate broad activity of PARP inhibitor in BRCA1/2 wild-type tumors KW Evans, E Yuca, A Akcakanat, SM Scott, NP Arango, X Zheng, K Chen, ... Clinical Cancer Research 23 (21), 6468-6477, 2017 | 53 | 2017 |
| Electrochemical studies of camptothecin and its interaction with human serum albumin J Zhao, X Zheng, W Xing, J Huang, G Li International Journal of Molecular Sciences 8 (1), 42-50, 2007 | 49 | 2007 |
| Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations Y Jiang, GG Malouf, J Zhang, X Zheng, Y Chen, EJ Thompson, ... Oncotarget 6 (37), 39865, 2015 | 44 | 2015 |
| First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer … S Pairawan, M Zhao, E Yuca, A Annis, K Evans, D Sutton, L Carvajal, ... Breast Cancer Research 23, 1-15, 2021 | 40 | 2021 |
| Functional consequence of the MET-T1010I polymorphism in breast cancer S Liu, F Meric-Bernstam, N Parinyanitikul, B Wang, AK Eterovic, X Zheng, ... Oncotarget 6 (5), 2604, 2015 | 40 | 2015 |
| Combining neratinib with CDK4/6, mTOR, and MEK inhibitors in models of HER2-positive cancer M Zhao, S Scott, KW Evans, E Yuca, T Saridogan, X Zheng, H Wang, ... Clinical Cancer Research 27 (6), 1681-1694, 2021 | 37 | 2021 |
